Technology transfer in human vaccinology: A retrospective review on public sector contributions in a privatizing science field

Vaccine

Volumn 30, Issue 44, 2012, Pages 6230-6240

  Hendriks, Jan ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

BRICs; Developing country vaccine manufacturers network (DCVMN); Global access; Historical framework; Public sector contribution; Vaccine production technology transfer

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; VACCINE;

BACTERIAL INFECTION; BRAZIL; CHINA; DEVELOPING COUNTRY; DIPHTHERIA; DRUG MANUFACTURE; DRUG SAFETY; EUROPE; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNIZATION; INDIA; INFLUENZA; INTERNATIONAL COOPERATION; MEASLES; MEDICAL TECHNOLOGY; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY CONTROL; RECOMBINANT DNA TECHNOLOGY; REVIEW; ROTAVIRUS INFECTION; RUBELLA; SCALE UP; SMALLPOX; TETANUS; UNITED STATES; VACCINATION; VACCINE PRODUCTION; VACCINE PRODUCTION TECHNOLOGY TRANSFER; VIRUS INFECTION; WORLD HEALTH ORGANIZATION;

EID: 84866001507     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.087     Document Type: Review

References (87)

1. Watson M. Technology transfer from the perspective of IFPMA vaccine members. Presentation delivered at the WHO workshop on technology transfer for local manufacturing capacity of vaccines,; 2010 [accessed 03.05.12]. http://www.who.int/phi/news/Presentation11.pdf.
2. Blume S., Geesink I. Vaccinology: an industrial science?. Sci Cult 2000, 9(1):31.
3. Wilde H. What are today's orphaned vaccines?. Clin Infect Dis 2001, 33(September (5)):648-650.
4. WHO. Trends in local production of medicines and related technology transfer. Geneva,; 2011. http://www.who.int/phi/publications/local_production_trends/en/index.htm l.
5. WHO. Increasing access to vaccines through technology transfer and local production,; 2010. http://www.who.int/phi/publications/local_production_vaccines/en/index.h tml.
6. IFPMA. Technology transfer: a collaborative approach to improve global health. The research-based pharmaceutical industry experience; 2011. Available from: [cited 2012 May 2]; 65 pages. http://www.ifpma.org/.
7. IFPMA. Influenza vaccine manufacturers transfer production technology around the world. Issue Brief: innovation and collaboration: the backbone to preparing and responding to global pandemic threats. The research-based pharmaceutical industry's role; 2009. Available from: [cited 2012 May 2]; 9 pages. http://www.ifpma.org/.
8. Baijot M. Technology transfer and vaccines: The GSK experience. Presentation delivered at the WHO workshop on technology transfer for local manufacturing capacity of vaccines, Geneva, 1 December 2010; 2010 [cited 2012 May 2]; available from: http://www.who.int/phi/news/Presentation11.pdf.
9. Vagelos R. Medicines, science and merck 2004, Cambridge University Press, New York.
10. Sun Z., Ming L., Zhu X., Lu J. Prevention and control of hepatitis B in China. J Med Virol 2002, 67(July (3)):447-450.
11. Zhou Y.H., Wu C., Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) 2009, 122(January (1)):98-102.
12. Cortes M.D., Cardoso D., Fitzgerald J., Difabio J.L. Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives. Biologicals 2012, 40(1):3-14.
13. Milstien J.B., Gaule P., Kaddar M. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 2007, 25(44):7610-7619.
14. WHO Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 2011, 86(January (5)):38-43.
15. IPO. (Industrial Partnership Office U. Technology Transfer: The History. Available from: [cited 2012 May 3]. https://ipo.llnl.gov/data/assets/docs/TechTransfer.pdf.
16. Salicrup L, Rohrbaugh M. Partnerships for Innovation and Global Health: NIH International Technology Transfer Activities. Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices Available online at, 2007: 1709-18. http://wwwiphandbookorg%3a%20mihr/PIPRA/bioDevelopments-International%20 Institute.
17. Salicrup L.F., Fedorková L. Challenges and opportunities for enhancing biotechnology and technology transfer in developing countries. Biotechnol Adv 2006, 24:69-79.
18. Krattiger A, Mahoney RT, Nelsen L, Thomson JA, Bennett AB, Satyanarayana K, et al. Executive Guide to Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices. Available online at: MIHR/PIPRA/bioDevelopments-International Institute, 2007. http://www.iphandbook.org/.
19. Preaud J. ARVAC project: the Enabling Platform model. Presentation delivered at the WHO workshop on technology transfer for local manufacturing capacity of vaccines, Geneva, 1 December 2010; 2010 [cited 2012 May 3]; available from: http://www.who.int/phi/news/Presentation11.pdf.
20. LaForce F.M., Konde K., Viviani S., Preziosi MP The Meningitis Vaccine Project. Vaccine 2007, 25(September (Suppl. 1)):A97-A100.
21. Lee C-HR FC, inventor The USA as represented by the Secretary of the DHHS, Washington, DC, assignee. Polysaccharide-protein conjugate vaccines. USA. 2007 June 21.
22. Frasch C., Preziosi M.P., Laforce F.M. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). Hum Vaccin Immunother 2012, 8(June (6)).
23. Meningvax Eliminating epidemic meningitis in sub-Saharan Africa. 2012 [cited; Available from: http://www.meningvax.org/mission.php.
24. GHSi. Shifting Paradigm How the BRICS are reshaping global health and development; 2012 [cited 2012 May 15]; available from: http://www.ghsinitiatives.org/downloads/ghsi_brics_report.pdf.
25. IVI. Press release: IVI announces the prequalification of innovative cholera vaccine by the World Health Organization; 2011 [cited 2012 May 3]; available from: http://www.eurekalert.org/pub_releases/2011-11/ivi-iat111111.php.
26. Trach D.D., Clemens J.D., Ke N.T., Thuy H.T., Son N.D., Canh D.G., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997, 349(January (9047)):231-235.
27. Sáenz TW, Thorsteinsdóttir H, de Souza MC. Cuba and Brazil: an important example of south-south collaboration in health biotechnology. MEDICC Rev 2010;12(July (3)):4.
28. WHO. Global Learning Opportunities for Vaccine Quality; 2012. Available from: [cited 2012 June 29]. http://www.who.int/immunization_standards/vaccine_quality/gtn_index/en/.
29. NIBSC w. home page website. 2012 [cited 2012 June 29]; Available from: http://www.nibsc.ac.uk/about_us/mission.aspx.
30. van Wezel A.L. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 1967, 216(October (5110)):64-65.
31. van Hemert P., Kilburn D.G., van Wezel A.L. Homogeneous cultivation of animal cells for the production of virus and virus products. Biotechnol Bioeng 1969, 11(September (5)):875-885.
32. van Hemert P. Vaccine production as a unit process. Prog Ind Microbiol 1974, 13:151-271.
33. Blume S., Geesink I. A brief history of polio vaccines. Science 2000, 288(Jun (5471)):1593-1594.
34. SIIL. Press release: Serum Institute of India Ltd. (SIIL) acquires Bilthoven Biologicals of Netherlands; 2012 [cited 2012 July 19]; available from: http://www.seruminstitute.com/content/news_9.htm.
35. Halstead SB Tissue culture-based rabies vaccines: vaccine production technology transfer. Rev Infect Dis 1988, 10(November-December (Suppl. 4)):S764-S765.
36. Halstead SB. Vaccines are Forever: A Short history of the RF/WHO rabies vaccine production technology transfer Project. Paper presented in seminar on future prospects on vaccine production technology, VECOL, Bogota, Colombia, 21 January 2000. 2001 [cited 2012 May 3]; available from: http://bariconsultants.com/attachments/Vaccines%20r%20Forever.pdf.
37. Hendriksen C.F., vd Gun J.W., Nagel J., Kreeftenberg J.G. The toxin binding inhibition test as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of tetanus antitoxin in human sera. J Biol Stand 1988, 16(October (4)):287-297.
38. Hong H.A., Ke N.T., Nhon T.N., Thinh N.D., van der Gun J.W., Hendriks J.T., et al. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Bull World Health Organ 1996, 74(3):275-282.
39. Hendriksen C.F., van der Gun J.W., Marsman F.R., Kreeftenberg J.G. The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid. Biologicals 1991, 19(January (1)):23-29.
40. Kreeftenberg J.G., van der Gun J., Marsman F.R., Sekhuis V.M., Bhandari S.K., Maheshwari S.C. An investigation of a mouse model to estimate the potency of the diphtheria component in vaccines. J Biol Stand 1985, 13(July (3)):229-234.
41. Kreeftenberg J.G., van der Gun J., Marsman F.R., van Asten J.A., Sekhuis V.M., Hendriksen C.F. A mouse model to estimate the potency of the diphtheria component in combined vaccines. Dev Biol Stand 1986, 64:21-24.
42. WHO. Annex 2. Requirements for diphtheria, tetanus, pertussis and combined vaccines (revised 1989). Technical Report Series 800; 1990. p. 87-179 [cited 2012 May 12]; available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/dtp/WHO_T RS_800_(part2)_DTPA2.pdf.
43. Hong H.A., Hendriks J. The use of alternatives to animal tests in developing countries. Dev Biol Stand 1999, 101:209-214.
44. WHO. Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Immunization; 1997 [cited 2012 May 15]; available from: http://whqlibdoc.who.int/hq/1997/WHO_VSQ_97.04_(parts1-2).pdf.
45. Biotech R. Press release: Rhein Biotech enters into development of combination vaccines with two renowned vaccine producers; 1999 [cited 2012 May 17]; available from: http://www.evaluatepharma.com/Universal/View.aspx%3Ftype=Story%26id=3427 8.
46. Milstien J., Belgharbi L. Regulatory pathways for vaccines for developing countries. Bull World Health Organ 2004, 82(February (2)):128-133.
47. World Bank Implementation Completion Rapport Rural Health and Preventive Medicine Project (Loan 2723-CHA/Credit 1713-CHA); Report No. 18893; 1999; 37 pages.
48. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980, 152(August (2)):361-376.
49. Kreeftenberg H, Hamidi, A. Annex 5: lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. Intellectual Property Rights and Vaccines in Developing Countries, WHO/IVB/0421; 2004; Geneva: WHO, Access to Technology, Immunization Vaccines and Biologicals; 2004:p. 5.
50. Beurret M., Hamidi A., Kreeftenberg J. Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries. Vaccine 2012, 30(33):4897-4906.
51. Friede M., Serdobova I., Palkonyay L., Kieny M.P. Technology transfer hub for pandemic influenza vaccine. Vaccine 2009, 27(5):631-632.
52. van Boxtel R. Whole or split? International technology platform for influenza vaccines (ITPIV) In: WHO Report of the fifth meeting with international partners on prospects for influenza vaccine technology transfer to developing country vaccine manufacturers, page 17; 2012 [cited 2012 May 17]; available from: http://whqlibdoc.who.int/publications/2012/9789241503518_eng.pdf.
53. Hendriks J., Holleman M., de Boer O., de Jong P., Luytjes W An international technology platform for influenza vaccines. Vaccine 2011, 29(July (Suppl. 1)):A8-A11.
54. Collin N., Dubois P.M. The Vaccine Formulation Laboratory: a platform for access to adjuvants. Vaccine 2011, 29(July (Suppl. 1)):A37-A39.
55. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34(June (2)):155-158.
56. Bakker W.A., Thomassen Y.E., Van't Oever A.G., Westdijk J., van Oijen M.G., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29(41):7188-7196.
57. WHO. Call for Expressions of Interest (EoI). Developing Sabin-Inactivated Polio Vaccine (sIPV); 2012 [cited 2012 May 15]; available from: http://www.polioeradication.org/Portals/0/Document/Research/EOI_POL_2012 0427.pdf.
58. Bozeman B. Technology transfer and public policy: a review of research and theory. Res Policy 2004, 29:627-655.
59. UNICEF. Vaccine Procurement for Low and Middle Income Countries: where we are now and looking forward; 2012 [cited 2012 May 15]; available from: http://www.unicef.org/supply/files/4._UNICEF_vaccine_procurement_overvie w.pdf.
60. Barton J. New Trends in Technology Transfer Implications for National and International Policy: ICTSD International Centre for Trade and Sustainable Development; Issue Paper no. 18; 2007.
61. Barton J, Ezekiel J. The patents-based pharmaceutical development process. Rationale, problems, and potential reforms. JAMA 2006; 294(16):7.
62. Barton J. Vaccines: technology transfer to the developing world. Stanford University Lecture; 2006 [cited 2012 May 2]; available from: http://iis-db.stanford.edu/evnts/4341/vaccine_technology_RIP.ppt.
63. WHO. BLG/UNDP/77.2 Manual for the production and control of vaccines: Tetanus Toxoid. Geneva; 1977.
64. WHO. BLG/UNDP/77.3 Manual for the production and control of vaccines: Pertussis Vaccine; 1977.
65. WHO. BLG/UNDP/77.1 Manual for the production and control of vaccines: Diphtheria Toxoid. Geneva; 1977.
66. UNIDO, V. 83-63529. The manufacture of vaccines in developing countries. Second Consultation on the Pharmceutical Industry, Budapest, 21-25 November 1983, 1983: 12 pages.
67. UNIDO. IS.402. Prospects for production of vaccines and other immunizing agents in developing countries. Sectoral Studies Series No. 4, 1983: 79 pages.
68. Csizer C BA, Cohen H, de Haan, HH, Ruitenberg EJ,van Wezel AL, van Ramshort JD, van Steenis, G, Sandtke J, Spelt C, Boonstopple F, Janssen G. UNIDO Model programme for the production of vaccines in developing countries. UC/GLO/84/120V.86 61649, 1986: 178 pages.
69. WHO. Transfer of technology for rabies vaccine production: new strains availale for Vero and BHK cell cultures. Bulletin of the World Health Organisation 1987; 65(6):1.
70. Paulson T. Vaccine program hopes for success where others failed. Seattle Post 2001 [cited 2012 2 May]; available from: http://www.seattlepi.com/news/article/Vaccine-program-hopes-for-success- where-others-1050907.php%23ixzz1rv11M7s8.
71. Gavaghan H. UN to end children's vaccine initiative. Science 1999, 283(March (5410)):1992-1993.
72. Milstien JG, B, Kane M, di Fabio JL, Homma A. Global DTP manufacturing capacity and capability. Status report: January 1995. Vaccine, pp. 31 Z-320, 1996 1996;14(4):8.
73. Milstien J, Batson A, Meaney W. A systematic method for evaluating the potential viability of local vaccine producers. Vaccine 1997 August-September;15(12-13):1358-63.
74. WHO. Study of donor inputs to vaccine production. WHO/V&B/99.21; 1999 [cited 2012 May 12]; 18 pages. Available from: http://whqlibdoc.who.int/hq/1999/WHO_V%26B_99.21.pdf.
75. WHO. Ensuring the quality of locally produced vaccines and the viability of local production. WHO/VSQ/90.82. 1990.
76. Milstien J. Landscape Analysis WHO's Role in Supporting Emerging Vaccine Manufacturers. Promoting the availability and affordability of high quality vaccines of public health priority. Paper presented to SAGE; 2010 [cited 2012 May 2]; available from: http://www.who.int/immunization/sage/1_Final_landscape_analysis_Milstien_19_October_2010.pdf.
77. Jadhav S., Datla M., Kreeftenberg H., Hendriks J. The developing countries vaccine manufacturers' network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008, 26(March (13)):1611-1615.
78. Poeloengan T., Raw I., Martinez L.H., El-Abbadi M. Developing country vaccine manufacturers network (DCVMN), 26-27 April 2001, Bandung, Indonesia. Vaccine 2001, 20(November (3-4)):285-287.
79. Plahte J. Is the pneumococcal vaccine advance market commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers. Vaccine 2012, 30(March (14)):2462-2466.
80. WHO. Global strategy and plan of action on public health, innovation and intellectual property; 2011 [cited 2011 29 December]; available from: http://www.who.int/phi/about/en/.
81. Friede M., Palkonyay L., Alfonso C., Pervikov Y., Torelli G., Wood D., et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011, 29(July (Suppl. 1)):A2-A7.
82. GAVI. Key figures: donor contributions & pledges. 2012 [cited; available from: http://www.gavialliance.org/funding/donor-contributions-pledges/.
83. Archibugi A.B.K. The global governance of communicable diseases; the case for vaccine R&D. Law Policy 2005, 27(1):33-51.
84. Nelson R. Introduction to the rate and direction of inventive activity: economic and social factors;. A conference of the Universities-National Bureau Committee for Economic Research and the Committee on Economic Growth of the Social Science Research Council Princeton: 1962, 1-16. Princeton Univ. Press. Bureau U-N (Ed.).
85. PATH. New rotavirus vaccines, more hope: PATH is working with partners in India, China, and elsewhere to advance promising new rotavirus vaccines; 2012 [cited 2012 May 3]; available from: http://www.path.org/projects/rotavirus_vaccine.php.
86. Boxtel van R. Whole or split? International technology platform for influenza vaccines (ITPIV) In: WHO Report of the fifth meeting with international partners on prospects for influenza vaccine technology transfer to developing country vaccine manufacturers, page 17; 2012 [cited 2012 May 17]; available from: http://whqlibdoc.who.int/publications/2012/9789241503518_eng.pdf.
87. Rourou S., van der Ark A., van der Velden T., Kallel H. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine 2007, 25(May (19)):3879-3889.